ArticlePharmacoEconomics2012
Value of information and pricing new healthcare interventions.
Article in PharmacoEconomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Globally optimal trial design and risk sharing arrangements are key to avoiding opportunity costs of delay and enabling equitable, feasible and effective global vaccine research and implementation in current or future pandemics.Frontiers in public health · 2022Article
- Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design.CPT: pharmacometrics & systems pharmacology · 2021Article
- Value of information methods to design a clinical trial in a small population to optimise a health economic utility function.BMC medical research methodology · 2018Article
- Decision-theoretic designs for small trials and pilot studies: A review.Statistical methods in medical research · 2016Review
- Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.HIV clinical trials · 2015Article
- Computing Expected Value of Partial Sample Information from Probabilistic Sensitivity Analysis Using Linear Regression Metamodeling.Medical decision making : an international journal of the Society for Medical Decision Making · 2015Article
- Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample: A Fast, Nonparametric Regression-Based Method.Medical decision making : an international journal of the Society for Medical Decision Making · 2015Article
- Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.PloS one · 2015Article
- Can the real opportunity cost stand up: displaced services, the straw man outside the room.PharmacoEconomics · 2014Article
- Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing.PharmacoEconomics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous application of value-of-information methods to optimal clinical trial design have predominantly taken a societal decision-making perspective, implicitly assuming that healthcare costs are covered through public expenditure and trial research is funded by government or donation-based philanthropic agencies. In this paper, we consider the interaction between interrelated perspectives of a societal decision maker (e.g. the National Institute for Health and Clinical Excellence [NICE] in the UK) charged with the responsibility for approving new health interventions for reimbursement and the company that holds the patent for a new intervention. We establish optimal decision making from societal and company perspectives, allowing for trade-offs between the value and cost of research and the price of the new intervention. Given the current level of evidence, there exists a maximum (threshold) price acceptable to the decision maker. Submission for approval with prices above this threshold will be refused. Given the current level of evidence and the decision maker's threshold price, there exists a minimum (threshold) price acceptable to the company. If the decision maker's threshold price exceeds the company's, then current evidence is sufficient since any price between the thresholds is acceptable to both. On the other hand, if the decision maker's threshold price is lower than the company's, then no price is acceptable to both and the company's optimal strategy is to commission additional research. The methods are illustrated using a recent example from the literature.
Indexed as
Identifiers
22591129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.